Bengt Ågerup resumes as President for Q-Med

BENGT ÅGERUP RESUMES AS PRESIDENT FOR Q-MED · Bengt Ågerup, Q-Med's founder and main owner, resumes the position of President of Q-Med with immediate effect. Bengt Ågerup was Q-Med's President up until April 1999. Since December 2000 he has had the position of executive Chaiman of the Board. He now once again resumes the position of President with immediate effect and thereby succeeds Per Olof Wallström, who is leaving the company. "Q-Med is about to enter one of the most important phases in its development of becoming an internationally well established company. The work on the Board does not give me enough involvement in the company's inner business activities. Amongst many other things, two new products will be introduced on the market on the basis of my inventions. This requires closeness and great commitment on my part. I look forward to once again being more operative and instigative in these important undertakings that the company has to fulfil," says Bengt Ågerup. "I have had just over two very rewarding and stimulating years as President of Q-Med. The company has had and has a fantastic development and potential," says Per Olof Wallström. Bengt Ågerup founded Q-Med in 1987. In 1995 he filed the patent which protects Q-Med's base technology, the production of NASHA (Non-Animal Stabilized Hyaluronic Acid). Today he owns 47.9 percent of the shares and votes in Q-Med through his company Agerup Holding. June 15, 2001 Uppsala, Sweden Q-Med AB (publ) The Board Queries should be addressed to Bengt Ågerup, President and CEO, on +46(0)18-474 90 00 or +46(0)70-974 90 25 and Per Olof Wallström, +46(0)70-974 90 70. Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. All products are based on the company's patented technology for the production of NASHA - Non-Animal Stabilized Hyaluronic Acid. Q-Med's operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation. The products RESTYLANE, RESTYLANE Fine Lines and PERLANE are used for the filling out of lips and facial wrinkles and today account for the majority of sales. DUROLANE, Q-Med's product for the treatment of osteoarthritis in the knee-joint, is approved in Europe and further documentation is ongoing. DEFLUX is a product which has been approved in Europe for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children and stress urinary incontinence in women. Since July 2000 Q-Med has held a majority interest in the American biotechnology company Ixion Biotechnology, Inc., which carries out research within cell therapy for diabetes. Q-Med today has 220 employees, with just above 150 at the company's production facility and head office in Uppsala, 20 at Ixion and the remainder in wholly owned foreign subsidiaries. The Q-Med share has been listed on the O-list of the Stockholm Stock Exchange since December 1999. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q- med.com. Home page: www.q-med.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.bit.se/bitonline/2001/06/15/20010615BIT00140/bit0001.doc http://www.bit.se/bitonline/2001/06/15/20010615BIT00140/bit0001.pdf